A study to predict the response to Anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy at an early stage on 68Gallium-PSMA-11 PET/CT in patients of metastatic renal cell cancer
Not Applicable
Completed
- Conditions
- Health Condition 1: C649- Malignant neoplasm of unspecifiedkidney, except renal pelvis
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 27
Inclusion Criteria
1. Adults = 18 years of age
2. Biopsy proven metastatic Renal Cell Cancer
3. Planned for targeted TKI therapy (first and second line).
4. Life expectancy > 6 months.
5. Patient consent to participate in the study.
Exclusion Criteria
1. Pregnant or lactating women.
2. Active malignancy other than renal cell cancer.
3. Tyrosine Kinase Inhibitor Therapy (TKI) within 4 weeks prior to enrolment.
4. Patients not giving consent to participate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Qualitative and quantitative (SUVmax) response to treatment on 68Ga-PSMA-11 PET/CT according to adapted PERCIST criteriaTimepoint: baseline and 1 month
- Secondary Outcome Measures
Name Time Method Correlation with anatomical size change on CT according to RECIST 1.1Timepoint: baseline and 3 months